Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.3814
+0.0014 (+0.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mainz Biomed N.V. - Ordinary Shares
< Previous
1
2
3
4
Next >
Mainz Biomed to Participate in Digestive Disease Week 2023
May 01, 2023
Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
April 27, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
April 26, 2023
The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Provides Full Year 2022 Financial Results
April 10, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
April 04, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
March 29, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Analysts Model Over 74% Upside For Mainz Biomed Stock Ahead Of Key 1/H 2023 Updates ($MYNZ)
March 23, 2023
Via
AB Newswire
Mainz Biomed ($MYNZ) Inks Accretive Partnership To Expand Marketing Reach Of ColoAlert Diagnostic, Analysts Model For Over 72% Upside ($MYNZ)
March 21, 2023
Via
AB Newswire
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
March 15, 2023
Labor Staber to actively market and sell ColoAlert to its physician and patient network.
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
March 21, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
In Focus: Mainz Biomed Nears Multiple Data Set Releases Expected To Fuel 2023 Growth ($MYNZ)
March 14, 2023
Via
AB Newswire
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
March 08, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed In Focus Ahead Of Two Data-Set Releases In 1H/2023 ($MYNZ)
March 07, 2023
Via
AB Newswire
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
March 01, 2023
Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer.
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
February 28, 2023
Virtual Fireside Chat via Paltalk Platform
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed’s Milestones Reached In 2022 Can Be Catalysts In 1/H 2023…Here’s Why ($MYNZ)
February 28, 2023
Via
AB Newswire
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
February 21, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
February 15, 2023
Continued roll-out in Europe with onboarding of new lab partners
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
January 18, 2023
Patient Access Initiative Addresses €1 Billion Annual Market in Germany
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Provides Year-End 2022 Corporate Review
January 03, 2023
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
December 20, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
December 06, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
November 29, 2022
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
November 22, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
November 15, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed Provides Third Quarter 2022 Update
November 02, 2022
From
Mainz BioMed NV
Via
GlobeNewswire
Mainz Biomed’s Colorectal And Pancreatic Cancer Screening Diagnostics Are More Than Life Savers, They Are Significant Value Drivers ($MYNZ)
October 17, 2022
Via
AB Newswire
Mainz Biomed Best-In-Class Colorectal Cancer Screening Diagnostics Expand International Presence, Targets Billion Dollar Market Opportunities ($MYNZ)
October 11, 2022
Via
AB Newswire
Mainz Biomed Best-In-Class Cancer Screening Diagnostics Tap Into Billion Dollar Market Opportunities ($MYNZ)
October 04, 2022
Via
AB Newswire
Mainz Biomed Stock Higher; Market Expansion Of Its Best-In-Class Cancer Diagnostics Power The Move ($MYNZ)
September 29, 2022
Via
AB Newswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.